PDF herunterladen
Semin Thromb Hemost 2000; 26(5): 539-546
DOI: 10.1055/s-2000-13210
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Asymmetric Dimethylarginine, Derangements of the Endothelial Nitric Oxide Synthase Pathway, and Cardiovascular Diseases

Rainer H. Böger, Stefanie M. Bode-Böger
  • Institute of Clinical Pharmacology, Medical School, Hannover, Germany
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
31. Dezember 2000 (online)

    Lizenzen und Reprints

ABSTRACT

Analogues of L-arginine that are chemically modified at the terminal guanidino nitrogen group, such as Nω-monomethy-L-arginine (L-NMMA), have been used for nitric oxide synthase inhibition. However, L-NMMA and other methylated L-arginine analogues are also endogenously formed. Among these, asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) have been shown to be the most abundant. Like L-NMMA, ADMA is an inhibitor of NO synthase, whereas SDMA is inactive. ADMA is synthesized by N-methyltransferases, a family of enzymes that methylate L-arginine residues within specific proteins. Free ADMA is released during proteolytic cleavage of methylated proteins; it can be detected in plasma and urine, but its intracellular concentrations appear to be much higher. ADMA is metabolized by the enzyme dimethylarginine dimethylaminohydrolase (DDAH), and inhibition of DDAH activity has been shown to lead to increased ADMA levels and endothelial dysfunction. Plasma levels of ADMA are elevated in end-stage renal failure, in atherosclerosis and hypercholesterolemia, in hypertension, and in heart failure. Although the molecular cause for elevation of ADMA concentration in these diseases has not been fully elucidated, evidence is accumulating that ADMA is one cause of endothelial dysfunction in these diseases. Moreover, it may be a marker or even a risk factor for cardiovascular disease. Therefore, pharmacological modulation of ADMA concentration may be a novel therapeutic target in cardiovascular diseases.

KEYWORD

Asymmetric dimethylarginine - atherosclerosis - nitric oxide synthase - cardiovascular risk factors - end-stage renal disease

REFERENCES

  • 1 Förstermann U, Closs E I, Pollock J S. Nitric oxide synthase isoenzymes. Characterization, purification, molecular cloning, and functions.  Hypertension . 1994;  23 1121-1131
    PubMedGoogle Scholar
  • 2 Moncada S, Higgs E A. The L-arginine-nitric oxide pathway.  N Engl J Med . 1993;  329 2002-2012
    CrossrefPubMedGoogle Scholar
  • 3 Wolf A, Zalpour C, Theilmeier G. Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans.  J Am Coll Cardiol . 1997;  29 479-485
    CrossrefPubMedGoogle Scholar
  • 4 Kubes P, Suzuki M, Granger D N. Nitric oxide: An endogenous modulator of leukocyte adhesion.  Proc Natl Acad Sci USA . 1991;  88 4651-4655
    CrossrefPubMedGoogle Scholar
  • 5 Böger R H, Bode-Böger S M, Kienke S. Dietary L-arginine decreases myointimal cell proliferation and vascular monocyte accumulation in cholesterol-fed rabbits.  Atherosclerosis . 1998;  136 67-77
    CrossrefPubMedGoogle Scholar
  • 6 Garg U C, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells.  J Clin Invest . 1989;  83 1774-1777
    CrossrefPubMedGoogle Scholar
  • 7 Böger R H, Bode-Böger S M, Mügge A. Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production.  Atherosclerosis . 1995;  117 273-284
    CrossrefPubMedGoogle Scholar
  • 8 Hogg N, Kalyanaraman B, Joseph J, Struck A, Parthasarathy S. Inhibition of low-density lipoprotein oxidation by nitric oxide. Potential role in atherogenesis.  FEBS Lett . 1993;  334 170-174
    CrossrefPubMedGoogle Scholar
  • 9 Creager M A, Cooke J P, Mendelsohn M E. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans.  J Clin Invest . 1990;  86 228-234
    CrossrefPubMedGoogle Scholar
  • 10 Tsao P S, Theilmeier G, Singer A H, Leung L LK, Cooke J P. L-Arginine attenuates platelet reactivity in hypercholesterolemic rabbits .  Arterioscler Thromb . 1994;  14 1529-1533
    PubMedGoogle Scholar
  • 11 Theilmeier G, Chan J, Zalpour C. Adhesiveness of mononuclear cells in hypercholesterolemic humans is normalized by dietary L-arginine.  Arterioscler Thromb Vasc Biol . 1997;  17 3557-3564
    PubMedGoogle Scholar
  • 12 Hansson G K, Seifert P S, Olsson G, Bondjers G. Immunohistochemical detection of macrophages and T lymphocytes in atherosclerotic lesions of cholesterol-fed rabbits.  Arterioscler Thromb . 1991;  11 745-750
    PubMedGoogle Scholar
  • 13 Böger R H, Bode-Böger S M, Frölich J C. The L-arginine-nitric oxide pathway: Role in atherosclerosis and therapeutic implications.  Atherosclerosis . 1996;  127 1-11
    CrossrefPubMedGoogle Scholar
  • 14 Böger R H, Bode-Böger S M, Szuba A. Asymmetric dimethylarginine: A novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia.  Circulation . 1998;  98 1842-1847
    PubMedGoogle Scholar
  • 15 Drexler H, Zeiher A M, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine.  Lancet . 1991;  338 1546-1550
    CrossrefPubMedGoogle Scholar
  • 16 Creager M A, Gallagher S J, Girerd X J. L-Arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans.  J Clin Invest . 1992;  90 1248-1253
    PubMedGoogle Scholar
  • 17 Böger R H, Bode-Böger S M, Brandes R P. Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: Comparison with lovastatin.  Circulation . 1997;  96 1282-1290
    PubMedGoogle Scholar
  • 18 Pollock J S, Förstermann U, Mitchell J A. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells.  Proc Natl Acad Sci USA . 1991;  88 10480-10484
    PubMedGoogle Scholar
  • 19 Böger R H, Bode-Böger S M, Thiele W. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease.  Circulation . 1997;  95 2068-2074
    PubMedGoogle Scholar
  • 20 Rees D D, Palmer R MJ, Schulz R, Hodson H F, Moncada S. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo.  Br J Pharmacol . 1990;  101 746-752
    PubMedGoogle Scholar
  • 21 Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure.  Lancet . 1992;  339 572-575
    CrossrefPubMedGoogle Scholar
  • 22 Kurose I, Wolf R, Grisham M B, Granger D N. Effects of an endogenous inhibitor of nitric oxide synthesis on postcapillary venules.  Am J Physiol . 1995;  268 H2224-H2231
    PubMedGoogle Scholar
  • 23 Faraci F M, Brian J E, Heistad D D. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase.  Am J Physiol . 1995;  269 H1522-H1527
    PubMedGoogle Scholar
  • 24 Segarra G, Medina P, Ballester R M. Effects of some guanidino compounds on human cerebral arteries.  Stroke . 1999;  30 2206-2211
    PubMedGoogle Scholar
  • 25 Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis .  J Cardiovasc Pharmacol . 1992;  20(suppl 12 S60-S62
    PubMedGoogle Scholar
  • 26 Fickling S A, Leone A M, Nussey S S, Vallance P, Whitley G SJ. Synthesis of NG , NG dimethylarginine by human endothelial cells.  Endothelium . 1993;  1 137-140
    PubMedGoogle Scholar
  • 27 Böger R H, Bode-Böger S M, Tsao P S. The endogenous NO synthase inhibitor asymmetric dimethylarginine (ADMA) exerts pro-atherosclerotic effects in cultured human endothelial cells.  Circulation . 1997;  96(Suppl) I-1588(Abst)
    PubMedGoogle Scholar
  • 28 Ito A, Tsao P S, Adimoolam S. Novel mechanism for endothelial dysfunction. Dysregulation of dimethylarginine dimethylaminohydrolase.  Circulation . 1999;  99 3092-3095
    CrossrefPubMedGoogle Scholar
  • 29 Azuma H, Sato J, Hamasaki H. Accumulation of endogenous inhibitors for nitric oxide synthesis and decreased content of L-arginine in regenerated endothelial cells.  Br J Pharmacol . 1995;  115 1001-1004
    PubMedGoogle Scholar
  • 30 McDermott J R. Studies on the catabolism of NG -methylarginine, NG ,NG -dimethylarginine and NG ,NG` -dimethylarginine in the rabbit.  Biochem J . 1976;  154 179-184
    PubMedGoogle Scholar
  • 31 MacAllister R J, Parry H, Kimoto M. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase .  Br J Pharmacol . 1996;  119 1533-1540
    CrossrefPubMedGoogle Scholar
  • 32 Rawal N, Rajpurohit R, Lischwe M A. Structural specifity of substrate for S-adenosylmethionine:protein arginine N-methyltransferases.  Biochim Biophys Acta . 1995;  1248 11-18
    PubMedGoogle Scholar
  • 33 MacAllister R J, Fickling S A, Whitley G SJ, Vallance P. Metabolism of methylarginines by human vasculature: implications for the regulation of nitric oxide synthesis.  Br J Pharmacol . 1994;  112 43-48
    CrossrefPubMedGoogle Scholar
  • 34 Kielstein J T, Böger R H, Bode-Böger S M. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: Relationship to treatment method and atherosclerotic disease.  J Am Soc Nephrol . 1999;  10 594-600
    PubMedGoogle Scholar
  • 35 Niu X F, Smith C W, Kubes P. Intracellular oxidative stress induced by nitric oxide synthesis inhibition increases endothelial cell adhesion to neutrophils.  Circ Res . 1994;  74 1133-1140
    PubMedGoogle Scholar
  • 36 Collins T, Read M A, Neish A S. Transcriptional regulation of endothelial cell adhesion molecules: NF-kB and cytokine-inducible enhancers.  FASEB J . 1995;  9 899-909
    PubMedGoogle Scholar
  • 37 Marui N, Offerman M K, Swerlik R. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells.  J Clin Invest . 1993;  92 1866-1874
    PubMedGoogle Scholar
  • 38 Ueda A, Okuda K, Ohno S. NF-kB and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene.  J Immunol . 1994;  153 2052-2063
    PubMedGoogle Scholar
  • 39 Tsao P S, Buitrago R, Chan J R, Cooke J P. Fluid flow inhibits endothelial adhesiveness. Nitric oxide and transcriptional regulation of VCAM-1.  Circulation . 1996;  94 1682-1689
    PubMedGoogle Scholar
  • 40 Tsao P S, Wang B Y, Buitrago R, Shyy J YJ, Cooke J P. Nitric oxide regulates monocyte chemotactic protein-1.  Circulation . 1997;  96 934-940
    PubMedGoogle Scholar
  • 41 MacAllister R J, Rambausek M H, Vallance P. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure.  Nephrol Dial Transplant . 1996;  11 2449-2452
    CrossrefPubMedGoogle Scholar
  • 42 Anderstam B, Katzarski K, Bergstrom J. Serum levels of NG , NG -dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients.  J Am Soc Nephrol . 1997;  8 1437-1442
    PubMedGoogle Scholar
  • 43 Tsao P S, McEvoy L M, Drexler H, Butcher E C, Cooke J P. Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine.  Circulation . 1994;  89 2176-2182
    PubMedGoogle Scholar
  • 44 Cayatte A J, Palacino J J, Horten K, Cohen R A. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits.  Arterioscler Thromb . 1994;  14 753-759
    CrossrefPubMedGoogle Scholar
  • 45 Naruse K, Shimizu K, Muramatsu M. Long-term inhibition of NO synthesis promotes atherosclerosis in the hypercholesterolemic rabbit thoracic aorta.  Arterioscler Thromb . 1994;  14 746-752
    PubMedGoogle Scholar
  • 46 Cooke J P, Singer A H, Tsao P. Antiatherosclerotic effects of L-arginine in the hypercholesterolemic rabbit.  J Clin Invest . 1992;  90 1168-1172
    CrossrefPubMedGoogle Scholar
  • 47 Bode-Böger S M, Böger R H, Kienke S. Chronic dietary supplementation with L-arginine inhibits platelet aggregation and thromboxane A2 synthesis in hypercholesterolaemic rabbits in vivo.  Cardiovasc Res . 1998;  37 756-764
    CrossrefPubMedGoogle Scholar
  • 48 Candipan R C, Wang B Y, Buitrago R, Tsao P S, Cooke J P. Regression or progression: Dependency on vascular nitric oxide.  Arterioscler Thromb Vasc Biol . 1996;  16 44-50
    PubMedGoogle Scholar
  • 49 Bode-Böger S M, Böger R H, Kienke S, Junker W, Frölich J C. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits.  Biochem Biophys Res Commun . 1996;  219 598-603
    CrossrefPubMedGoogle Scholar
  • 50 Surdacki A, Nowicki M, Sandmann J. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetrical dimethylarginine in men with essential hypertension .  J Cardiovasc Pharmacol . 1999;  33 652-658
    PubMedGoogle Scholar
  • 51 Hornig B, Arakawa N, Böger R H. Plasma levels of ADMA are increased and inversely related to endothelium-mediated vasodilation in patients with chronic heart failure: A new predictor of endothelial dysfunction?.  Circulation . 1998;  98(Suppl) I-318(Abst)
    PubMedGoogle Scholar
  • 52 Miyazaki H, Matsuoka H, Cooke J P. Endogenous nitric oxide synthase inhibitor. A novel marker of atherosclerosis .  Circulation . 1999;  99 1141-1146
    CrossrefPubMedGoogle Scholar
  • 53 Bode-Böger S M, Böger R H, Alfke H. L-Arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study.  Circulation . 1996;  93 85-90
    PubMedGoogle Scholar
  • 54 D'Orleans-Juste P, Mitchell J A, Wood E G, Hecker M, Vane J R. Comparison of the release of vasoactive factors from venous and arterial bovine cultured endothelial cells.  Can J Physiol Pharmacol . 1992;  70 687-694
    PubMedGoogle Scholar